No therapies targeting KRAS G12D mutation, occurring in ∼5% of pts with NSCLC, are available. In this first-in-human phase I study (NCT05382559), setidegrasib, a first-in-class protein degrader targeting KRAS G12D, had manageable safety and clinical activity. We present updated data for additional pts with NSCLC who received setidegrasib 600 mg monotherapy IV once weekly (recommended phase II dose).